Novartis AG
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
27.99%
Market Cap
240.46 Bil.
P/E Ratio
18.30
Dividend Yield
3.38 %
Earnings per Share
6.41 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 131.36 G | 0 Units |
| PRICE DETERMINATION TIME | 07/15/2026 / 09:56:45 PM | |
| DAILY VOLUME (UNITS) | 488 | |
| DAILY HIGH / LOW | 133.26 | 131.36 |
| PREV. DAY'S PRICE | 132.34 | (07/14) |
| CHANGE DAY BEFORE | -0.98 | -0.74 % |
| 52 WEEK HIGH / LOW | 144.1 (02/27) | 96.8 (08/06) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 8.53 | 7.63 | 6.41 | 5.47 | 6.62 |
| DIVIDENDS PER SHARE | 4.30 | 4.14 | 3.96 | 3.68 | 3.40 |
| DIVIDEND YIELD IN % | - | - | 3.38 % | 3.95 % | 3.89 % |
| DIVIDEND GROWTH IN % | - | - | 7.64 % | 8.18 % | 6.54 % |
| PRICE - EARNINGS RATIO | 15.78 | 17.64 | 18.30 | 17.02 | 13.21 |
| PRICE - BOOK RATIO | - | - | 5.72 | 4.39 | 4.42 |
| PRICE - SALES RATIO | - | - | 4.73 | 4.07 | 4.35 |
| PRICE - CASH FLOW RATIO | - | - | 13.48 | 11.63 | 13.67 |
Master Data
| WKN | 904278 |
| ISIN | CH0012005267 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Novartis |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Swiss Franc |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 1.83 Bil. |
| MARKET CAPITALISATION | 240.46 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| Performance | -3.99 % | 0.09 % | 1.85 % | 5.66 % | 27.99 % | - | - | 12.11 % |
| High | 136.80 | 140.24 | 140.24 | 144.10 | 144.10 | - | - | 144.10 |
| Low | 131.80 | 126.34 | 116.20 | 116.20 | 96.80 | - | - | 116.00 |
Novartis does not deliver dividend information
Company profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Structured products for Novartis AG
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.